Analytical Data
-
Gene name
WWP2
- Application
-
Alternative Names
AIP2; WWp2-like; Atrophin-1-interacting protein 2; NEDD4-like E3 ubiquitin-protein ligase WWP2
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O00308
-
Expression Region
His601~Glu870
-
Molecular Weight
34kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
WWP2, or WW domain-containing E3 ubiquitin ligase 2, has emerged as a significant player in the regulation of various cellular processes, including protein stability, signal transduction, and cell cycle control. Its role in the ubiquitin-proteasome system highlights its importance in protein degradation and modulation of key signaling pathways, particularly those involved in oncogenesis and cellular stress responses. Recent studies have implicated WWP2 in various diseases, including cancer, neurodegenerative disorders, and metabolic syndromes, prompting intensified research efforts to understand its structural and functional properties. Exploring WWP2 as a recombinant protein has offered insights into its enzymatic mechanisms and substrate interactions, facilitating the identification of novel therapeutic targets. The development of WWP2-specific inhibitors could pave the way for innovative treatments, leveraging the protein's unique functions in disease modulation. Understanding the molecular mechanisms driven by WWP2 thus holds substantial promise for advancing our knowledge of cellular regulation and developing effective interventions for related pathologies.
